SPRO Stock Price, Chart, Stats & News
Spero Therapeutics, Inc. (SPRO) does not currently pay a dividend.
SPRO chart
Fundamentals
Gross margin | 11.94% |
Operating margin | -0.04% |
Pretax margin | 14.82% |
Net margin | 14.38% |
Effective tax rate | 2.95% |
ROA | 12.44% |
ROE | 22.53% |
D/E | 0.05x |
Interest coverage ratio | – |
SPRO valuation
P/E | 9.21x |
P/S | 2.26x |
P/B | 2.21x |
P/CF | -10.34x |
P/FCF | -10.68x |
P/OCF | -10.34x |
PEG | 0.13x |
EV multiple | 31.51x |
About
Spero Therapeutics, Inc. is a biopharmaceutical firm in the clinical development stage, primarily focused on discovering, advancing, and commercializing innovative treatments for multi-drug resistant (MDR) bacterial infections and rare diseases within the United States. The company's pipeline includes several key therapeutic candidates: tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic designed to address complicated urinary tract infections (cUTIs), including pyelonephritis, in adult patients. SPR206, an intravenously administered agent specifically developed to combat MDR Gram-negative bacterial infections in hospital environments.
Similar securities
Based on sector and market capitalization
